Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
XOMA RoyaltyXOMA -0.10%41 PB Ratio is 4.24 as of Jul. 19, 2026, which is 2% above its 10-year median of 4.16. GuruFocus rates XOMA with a GF Score™ of 41/100 and a GF Value™ of $18.93 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,232 Biotechnology companies, XOMA Royalty ranks worse than 64.69% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-19), XOMA Royalty's share price is $40.17. XOMA Royalty's Book Value per Share for the quarter that ended in Mar. 2026 was $9.48. Hence, XOMA Royalty's PB Ratio of today is 4.24.
The historical rank and industry rank for XOMA Royalty's PB Ratio or its related term are showing as below:
XOMA'
s PB Ratio Range Over the Past 10 Years
Min: 1.4 Med: 4.16 Max: 122.34
Current: 4.24
During the past 13 years, XOMA Royalty's highest PB Ratio was 122.34. The lowest was 1.40. And the median was 4.16.
XOMA's PB Ratio is ranked worse than 64.69% of 1232
companies
in the Biotechnology industry
Industry Median: 2.825
vs XOMA: 4.24
During the past 12 months, XOMA Royalty's average Book Value Per Share Growth Rate was 33.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -13.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -9.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of XOMA Royalty was 184.40% per year. The lowest was -116.90% per year. And the median was 0.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
XOMA Royalty PB Ratio Related Terms
XOMA Royalty PB Ratio Historical Data
* Premium members only.
The historical data trend for XOMA Royalty's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, XOMA Royalty's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XOMA Royalty PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, XOMA Royalty's PB Ratio distribution charts can be found below:
* The bar in red indicates where XOMA Royalty's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
XOMA Royalty's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
XOMA Royalty (XOMA) has a PB Ratio of 4.24 as of Jul. 19, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on XOMA Royalty and its competitors. This is near median its historical median of 4.16. Over the past decade, XOMA Royalty's PB Ratio has ranged from 1.40 to 122.34. According to the industry distribution chart, XOMA Royalty ranks #797 out of 1232 companies in the Biotechnology industry, placing it in the top 64.7%.
Is XOMA Royalty's PB Ratio too high?
XOMA Royalty's current PB Ratio of 4.24 is near median its 10-year median of 4.16. Over the past 10 years, this metric has ranged from a low of 1.40 to a high of 122.34. The Biotechnology industry median PB Ratio is 2.83. XOMA Royalty's value of 4.24 is 50.1% above this industry median. Based on the distribution chart, XOMA Royalty ranks #797 out of 1232 companies in the Biotechnology industry, which is below the industry midpoint. Overall, XOMA Royalty has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does XOMA Royalty's PB Ratio compare to CLYM and CTMX?
According to the Biotechnology industry distribution chart, XOMA Royalty ranks #797 out of 1232 companies for PB Ratio. This places XOMA Royalty in the lower half of its industry. The industry median PB Ratio is 2.83. XOMA Royalty's value of 4.24 is 50.1% above this benchmark. Historically, XOMA Royalty's own PB Ratio has ranged from 1.40 to 122.34 over the past decade. While the company's 10-year median is 4.16 vs. the industry median of 2.83, XOMA Royalty has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.83, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. XOMA Royalty's current PB Ratio of 4.24 is 50.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on XOMA Royalty and its competitors. For the Biotechnology industry, the median PB Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. XOMA Royalty's current PB Ratio is 4.24, which is near median its own 10-year median of 4.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XOMA Royalty stock overvalued right now?
Based on GuruFocus' analysis, XOMA Royalty (XOMA) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.93, compared to a current price of $40.17 — trading 112.2% above its estimated fair value. The current PB Ratio is 4.24, which is near median its 10-year median of 4.16 and 50.1% above the Biotechnology industry median of 2.83. XOMA Royalty's overall GF Score™ is 41/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For XOMA Royalty (XOMA), the current PB Ratio is 4.24 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is XOMA Royalty (XOMA) Overvalued in 2026?
Based on GuruFocus' analysis, XOMA Royalty stock appears to be overvalued.
The current stock price of $40.17 is trading 112.2% above its estimated GF Value™ of $18.93.
GuruFocus considers XOMA Royalty to be Significantly Overvalued.
Key valuation signals for XOMA:
PB Ratio: 4.24 (near median its 10-year median of 4.16)
GF Value™: $18.93 vs. price of $40.17 (112.2% above fair value)
Industry Position: 50.1% above the Biotechnology median (#797 of 1232)
No single metric tells the full story. See the XOMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.
41GF Score
Get the complete analysis for XOMA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XOMA has been successfully added to your 
